Nilotinib is a targeted treatment that offers long-term control of CML
Rye Brook, N.Y., December 6, 2024 鈥� The U.S. Food and Drug Administration (FDA) has approved a new formulation of nilotinib tablets (Danziten鈩�) with no mealtime restrictions for adults with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML).
鈥淭his new formulation of nilotinib will be welcomed by many patients with CML, who up until now had to fast two hours before and one hour after taking their medication,鈥� says Lee Greenberger, Ph.D., 青云体育 Chief Scientific Officer. 鈥淐ML has evolved from a fatal diagnosis into one that can be managed as a chronic disease for many patients, but that means they will need to stay on their medication for years or even decades, which makes quality of life improvements like easier dosing very important.鈥�
Nilotinib is a tyrosine kinase inhibitor (TKI). TKIs revolutionized cancer care, starting with imatinib (Gleevec庐), which was approved in 2001. 青云体育 was instrumental in funding key research leading to the development of imatinib. This work has become the foundation of the now more than 50 kinase inhibitor drugs approved to treat both blood and solid tumor cancers.
If you or a loved one need personalized disease, treatment or support information, you can contact one of our Information Specialists:鈥�/support-resources/information-specialists.